Filing Flows › Boston Scientific (BSX) › Guidance history
Boston Scientific (BSX) guidance history: what it guided and what it reported
Boston Scientific gave guidance in 12 earnings releases on file since Jan 31, 2024. Of 7 guided periods since reported, it met or beat its own guidance 5 times (71%). Revenue: 5 of 7, on average +1.8% against the guided midpoint. Its releases raised guidance 9 times and lowered it once.
Revenue
Met or beat 5 of 7 periods (4 above, 1 within, 2 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q3 2026 | $5.4B (Jul 29, 2026) | $5.1B | below the range | -5.6% |
| Q2 2026 | $5.2B (Apr 22, 2026) | $5.4B | above the range | +4.6% |
| Q1 2026 | $5.3B (Feb 4, 2026) | $5.2B | below the range | -1.6% |
| Q4 2025 | $5.1B (Oct 22, 2025) | $5.3B | above the range | +4.4% |
| Q3 2025 | $5.1B (Jul 23, 2025) | $5.1B | within the range | +0.1% |
| Q2 2025 | $4.7B (Apr 23, 2025) | $5.1B | above the range | +8.5% |
| Q1 2025 | $4.6B (Feb 5, 2025) | $4.7B | above the range | +2.2% |
| Q4 2024 | $4.2B (Oct 23, 2024) | — | — | — |
| Q3 2024 | $4.1B (Jul 24, 2024) | — | — | — |
| Q2 2024 | $3.9B (Apr 24, 2024) | — | — | — |
GAAP EPS
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q1 2026 | $0.45 (Feb 4, 2026) | — | — | — |
| Q4 2025 | $0.51 (Oct 22, 2025) | — | — | — |
| Q3 2025 | $0.53 (Jul 23, 2025) | — | — | — |
| Q2 2025 | $0.45 (Apr 23, 2025) | — | — | — |
| Q1 2025 | $0.38 (Feb 5, 2025) | — | — | — |
| Q4 2024 | $0.32 (Oct 23, 2024) | — | — | — |
| Q3 2024 | $0.22 (Jul 24, 2024) | — | — | — |
| Q2 2024 | $0.33 (Apr 24, 2024) | — | — | — |
| Q1 2024 | $0.34 (Jan 31, 2024) | — | — | — |
Adjusted EPS
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q4 2026 | $3.16–$3.18 (Oct 28, 2026) | — | to be reported | — |
| Q3 2026 | $3.28–$3.32 (Jul 29, 2026) | — | — | — |
| Q2 2026 | $3.34–$3.41 (Apr 22, 2026) | — | — | — |
| Q1 2026 | $0.80 (Feb 4, 2026) | — | — | — |
| Q4 2025 | $0.75 (Oct 22, 2025) | — | — | — |
| Q3 2025 | $0.75 (Jul 23, 2025) | — | — | — |
| Q2 2025 | $0.75 (Apr 23, 2025) | — | — | — |
| Q1 2025 | $0.70 (Feb 5, 2025) | — | — | — |
| Q4 2024 | $0.63 (Oct 23, 2024) | — | — | — |
| Q3 2024 | $0.62 (Jul 24, 2024) | — | — | — |
The latest quarter
Boston Scientific, Q3 2026: revenue $5.1B (+1% year over year), operating margin 16.1%, net earnings $580M, operating cash flow $1.0B. The chart follows the revenue to costs, profit and cash.
Questions
Does Boston Scientific beat its guidance?
Boston Scientific gave guidance in 12 earnings releases on file since Jan 31, 2024. Of 7 guided periods since reported, it met or beat its own guidance 5 times (71%). Revenue: 5 of 7, on average +1.8% against the guided midpoint.
How often does Boston Scientific raise guidance?
Its earnings releases raised guidance 9 times and lowered it once since Jan 31, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.